5篇
您的检索式：作者名="Alessandra Mosca"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Structured zeolite NaX coatings on ceramic cordierite monolith supports for PSA applications显示文摘 | Alessandra Mosca Jonas Hedlund Paul A Webley | 2010 | Microp Mesop Mater2010，130，： | 1 |
| 2 | PCDDlFs removal efficiency by electrostatic precipitator and wetfine scrubber in an iron ore sintering plant 显示文摘 | Ettore Guerriero Alessandra Guarnieri Silvia Mosca | 2009 | Journal of Hazardous Materials2009，172，： | 1 |
| 3 | Cell-free DNA in the plasma of patients with systemic sclerosis显示文摘 | Marta Mosca Tiziana Giuliano Giovanna Cuomo Marica Doveri Chiara Tani Michele Curcio Giuseppina Abignano Francesca Feo Laura Bazzichi Alessandra Della Rossa Gabriele Valentini Stefano Bombardieri | 2009 | Clinical Rheumatology2009，，12： | 1 |
| 4 | Structured zeolite NaX coatings on ceramic cordierite monolith supports for PSA applications显示文摘 | Alessandra Mosca Jonas Hedlund Paul A Webley | 2010 | Microp Mesop Mater2010，130，： | 1 |
| 5 | First-line pazopanib in patients with advanced non-clear cell renal carcinoma:An Italian case series显示文摘BACKGROUND Non-clear cell(ncc)metastatic renal-cell carcinoma(RCC)has dismal results with standard systemic therapies and a generally worse prognosis when compared to its clear-cell counterpart.New systemic combination therapies have emerged for metastatic RCC(mRCC),but the pivotal phase III trials excluded patients with nccRCC,which constitute about 30%of metastatic RCC cases.AIM To provide a piece of real-life evidence on the use of pazopanib in this patient subgroup.METHODS The present study is a multicenter retrospective observational analysis aiming to assess the activity,efficacy,and safety of pazopanib as first-line therapy for advanced nccRCC patients treated in a real-life setting.RESULTS Overall,48 patients were included.At the median follow-up of 40.6 mo,the objective response rate was 27.1%,the disease control rate was 83.3%,and the median progression-free survival and overall survival were 12.3(95%confidence interval[CI]:3.6-20.9)and 27.7(95%CI:18.2-37.1)mo,respectively.Grade 3 adverse events occurred in 20%of patients,and no grade 4 or 5 toxicities were found.CONCLUSION Pazopanib should be considered as a good first-line option for metastatic RCC with variant histology. | Sebastiano Buti Melissa Bersanelli Francesco Massari Ugo De Giorgi Orazio Caffo Gaetano Aurilio Umberto Basso Giacomo Carteni Claudia Caserta Luca Galli Francesco Boccardo Giuseppe Procopio Gaetano Facchini Giuseppe Fornarini Alfredo Berruti Elena Fea Emanuele Naglieri Fausto Petrelli Roberto Iacovelli Camillo Porta Alessandra Mosca | 2021 | World Journal of Clinical Oncology2021，12，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员